Fulgent Genetics (NASDAQ:FLGT – Get Free Report) and Veeva Systems (NYSE:VEEV – Get Free Report) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, profitability, valuation, analyst recommendations, institutional ownership and risk.
Earnings and Valuation
This table compares Fulgent Genetics and Veeva Systems”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Fulgent Genetics | $322.67 million | 1.46 | -$60.51 million | ($2.39) | -6.63 |
| Veeva Systems | $3.20 billion | 8.38 | $908.91 million | $5.41 | 30.31 |
Profitability
This table compares Fulgent Genetics and Veeva Systems’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Fulgent Genetics | -23.04% | -3.24% | -2.97% |
| Veeva Systems | 28.44% | 13.80% | 11.39% |
Analyst Recommendations
This is a summary of recent ratings and recommmendations for Fulgent Genetics and Veeva Systems, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Fulgent Genetics | 1 | 2 | 2 | 0 | 2.20 |
| Veeva Systems | 1 | 9 | 16 | 0 | 2.58 |
Fulgent Genetics currently has a consensus target price of $27.00, suggesting a potential upside of 70.35%. Veeva Systems has a consensus target price of $276.52, suggesting a potential upside of 68.63%. Given Fulgent Genetics’ higher possible upside, equities research analysts plainly believe Fulgent Genetics is more favorable than Veeva Systems.
Institutional & Insider Ownership
48.1% of Fulgent Genetics shares are owned by institutional investors. Comparatively, 88.2% of Veeva Systems shares are owned by institutional investors. 36.2% of Fulgent Genetics shares are owned by insiders. Comparatively, 10.6% of Veeva Systems shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Risk & Volatility
Fulgent Genetics has a beta of 0.88, meaning that its stock price is 12% less volatile than the S&P 500. Comparatively, Veeva Systems has a beta of 0.92, meaning that its stock price is 8% less volatile than the S&P 500.
Summary
Veeva Systems beats Fulgent Genetics on 12 of the 14 factors compared between the two stocks.
About Fulgent Genetics
Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company’s clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in El Monte, California.
About Veeva Systems
Veeva Systems Inc. provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States. The company also provides Veeva Development Cloud, a suite of applications for the clinical, regulatory, quality, and safety functions, including Veeva Vault Clinical, Veeva Vault RIM, Veeva Vault Safety, and Veeva Vault Quality; Veeva QualityOne, a quality and document management, and training solution; Veeva RegulatoryOne, a solution that helps companies to manage regulatory submission content; and Veeva Claims addresses the end-to-end product and marketing claims management process. In addition, it offers professional and support services, including implementation and deployment planning and project management; requirements analysis, solution design, and configuration; systems environment management and deployment services; services focused on advancing or transforming business and operating processes related to Veeva solutions; data migration and systems integrations technical consulting services; training on its solutions; and ongoing managed services, such as outsourced systems administration. The company was formerly known as Verticals onDemand, Inc. and changed its name to Veeva Systems Inc. in April 2009. Veeva Systems Inc. was incorporated in 2007 and is headquartered in Pleasanton, California.
Receive News & Ratings for Fulgent Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fulgent Genetics and related companies with MarketBeat.com's FREE daily email newsletter.
